InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for stroke prevention, announced that its Compensation Committee has approved inducement grants to six new non-executive employees totaling 138,442 shares of restricted stock.
These grants were made outside of InspireMD's 2021 Equity Compensation Plan with a grant date of February 5, 2025. The inducement plan is exclusively used for equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement for joining the company.
The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remainder vesting in two equal installments on the second and third anniversaries, contingent upon continued employment with InspireMD as of these vesting dates.
InspireMD (Nasdaq: NSPR), sviluppatore del sistema di stent carotideo CGuard™ Prime per la prevenzione dell'ictus, ha annunciato che il suo Comitato per la Compensazione ha approvato concessioni di incentivazione a sei nuovi dipendenti non esecutivi per un totale di 138.442 azioni di stock vincolato.
Queste concessioni sono state effettuate al di fuori del Piano di Compensazione Azionaria 2021 di InspireMD con una data di concessione del 5 febbraio 2025. Il piano di incentivazione è utilizzato esclusivamente per premi azionari a individui che non erano precedentemente dipendenti di InspireMD, o dopo un periodo di non occupazione genuino, come incentivo per unirsi all'azienda.
Le azioni vincolate seguono un programma di maturazione di tre anni, con un terzo che matura al primo anniversario e il resto che matura in due rate uguali nei secondi e terzi anniversari, a condizione che il dipendente continui a lavorare con InspireMD in queste date di maturazione.
InspireMD (Nasdaq: NSPR), desarrollador del sistema de stent carotídeo CGuard™ Prime para la prevención de accidentes cerebrovasculares, anunció que su Comité de Compensación ha aprobado concesiones de incentivo a seis nuevos empleados no ejecutivos por un total de 138,442 acciones de stock restringido.
Estas concesiones se realizaron fuera del Plan de Compensación de Capital de InspireMD de 2021 con una fecha de concesión del 5 de febrero de 2025. El plan de incentivo se utiliza exclusivamente para premios de capital a individuos que no eran empleados previamente de InspireMD, o tras un período genuino de no empleo, como incentivo para unirse a la empresa.
Las acciones restringidas siguen un programa de adquisición de tres años, con un tercio adquiriéndose en el primer aniversario y el resto en dos cuotas iguales en el segundo y tercer aniversarios, condicionado a la continuación del empleo con InspireMD en estas fechas de adquisición.
InspireMD (Nasdaq: NSPR)는 뇌졸중 예방을 위한 CGuard™ Prime 경동맥 스텐트 시스템의 개발업체로, 보상위원회가 유인 보상을 승인했다고 발표했습니다. 이는 6명의 새로운 비상임 직원에게 총 138,442주 제한 주식을 부여하는 것입니다.
이 보상은 InspireMD의 2021년 주식 보상 계획 외부에서 이루어졌으며, 부여일은 2025년 2월 5일입니다. 유인 계획은 InspireMD의 이전 직원이 아니었던 개인 또는 정당한 비고용 기간 이후에 회사를 합류하도록 유인하기 위해 독점적으로 사용됩니다.
제한 주식은 3년의 베스팅 일정을 따르며, 1주년에는 1/3이 베스트되고 나머지는 2주년과 3주년의 두 번에 걸쳐 동일한 비율로 베스팅됩니다. 이는 베스팅 날짜에 InspireMD에서 계속 근무하는 조건입니다.
InspireMD (Nasdaq: NSPR), développeur du système de stent carotidien CGuard™ Prime pour la prévention des AVC, a annoncé que son Comité de Rémunération a approuvé des attributions incitatives à six nouveaux employés non exécutifs, totalisant 138 442 actions restreintes.
Ces attributions ont été faites en dehors du Plan de Rémunération en Actions 2021 d'InspireMD, avec une date d'attribution du 5 février 2025. Le plan d'incitation est utilisé exclusivement pour les attributions d'actions à des individus qui n'étaient pas auparavant employés par InspireMD, ou après une période de non-emploi authentique, comme incitation à rejoindre l'entreprise.
Les actions restreintes suivent un calendrier de vesting de trois ans, avec un tiers qui devient acquéreur au premier anniversaire et le reste qui devient acquéreur en deux versements égaux aux deuxième et troisième anniversaires, sous réserve de la poursuite de l'emploi avec InspireMD à ces dates de vesting.
InspireMD (Nasdaq: NSPR), Entwickler des CGuard™ Prime Carotis-Stentsystems zur Schlaganfallprävention, gab bekannt, dass der Vergütungsausschuss Incentive-Zuschüsse an sechs neue nicht-executive Mitarbeiter in Höhe von insgesamt 138.442 Aktien beschränkter Aktien genehmigt hat.
Diese Zuschüsse wurden außerhalb des Aktienvergütungsplans 2021 von InspireMD gewährt, mit einem Gewährungsdatum vom 5. Februar 2025. Der Incentive-Plan wird ausschließlich für Eigenkapitalvergaben an Personen verwendet, die zuvor keine Mitarbeiter von InspireMD waren oder nach einer echten Phase der Nichtbeschäftigung, um sie zur Mitarbeit im Unternehmen zu bewegen.
Die beschränkten Aktien folgen einem drei Jahre dauernden Vesting-Plan, wobei ein Drittel am ersten Jahrestag und der Rest in zwei gleichen Raten am zweiten und dritten Jahrestag fällig wird, vorausgesetzt, dass die Beschäftigung bei InspireMD an diesen Vesting-Daten fortgesetzt wird.
- Hired six new non-executive employees, indicating company growth
- Offering equity incentives to attract new talent
- Potential dilution for existing shareholders from 138,442 new restricted shares
MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of February 5, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
What inducement grants did InspireMD (NSPR) announce on February 25, 2025?
What is the vesting schedule for NSPR's recently announced restricted stock grants?
Why did InspireMD (NSPR) issue inducement grants outside its regular equity compensation plan?
How many new employees received inducement grants from InspireMD (NSPR) in February 2025?
What product is InspireMD (NSPR) known for developing according to their February 2025 announcement?
